SCHEMBL3115806

SCHEMBL3115806

Cc1cccc(-c2ccc3c(C(N)=O)c(-c4ccc(Cl)cc4Cl)oc3c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
DPP4 P27487 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CNR1 P21554 3/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 2/20 0.37
GRM2 Q14416 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RIPK2 O43353 1/20 0.36
DHODH Q02127 1/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098337 0.81 HPGD (0.41) MEN1KMT2ACNR1RAB9AKDM4E
SCHEMBL3102599 0.74 MCL1 (0.44) MEN1KMT2ARAB9AKDM4EHPGD
SCHEMBL13335688 0.72 SMN1; SMN2 (0.43) CA12CA9CNR1RAB9AKDM4E
SCHEMBL3102308 0.72 MCL1 (0.50) CA12CA9MEN1KMT2ACNR1
SCHEMBL3098001 0.70 ALOX5 (0.44) MEN1KMT2ARAB9AKDM4EHPGD
SCHEMBL31723140 0.70 MAPT (0.59) CA12CA9MEN1KMT2ARAB9A
SCHEMBL20919306 0.70 MAPT (0.59) CA12CA9MEN1KMT2ARAB9A
SCHEMBL13335809 0.69 FLT1 (0.40) CA12CA9MEN1KMT2ACNR1
SCHEMBL10703217 0.69 DPP4 (0.52) DPP4CNR1RAB9AHPGDLMNA
SCHEMBL5013980 0.68 SMN1; SMN2 (0.42) CA12CA9MEN1KMT2ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803956-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2010-09-28 US disclosed
US-20090292014-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS ZHANG CHENGZHI 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292014-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS PCNA, MKI67, CDK4 CA12 4759/4885CA9 4838/4885DPP4 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.